Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
OTCMKTS:BICX

Biocorrx 5/15/2024 Earnings Report

Biocorrx logo
$0.24 0.00 (0.00%)
As of 05/4/2026 09:30 AM Eastern
ProfileEarnings HistoryForecast

Biocorrx EPS Results

Actual EPS
-$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biocorrx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biocorrx Announcement Details

Quarter
Date
5/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biocorrx's next earnings date is estimated for Monday, May 11, 2026, based on past reporting schedules.

Conference Call Resources

Biocorrx Earnings Headlines

BioCorRx Inc.
April 21, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/BICX/financials
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-inc-announces-issuance-u-123000683.html
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without ...
January 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-inc-announces-initiation-clinical-133000445.html
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-announces-appointment-louis-lucido-133000529.html
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
December 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-provides-otc-markets-quotation-133000381.html
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

View Biocorrx Profile
Earnings Tools